Question 1

What are the potential side effects of VIP peptides?

Accepted Answer

There are three lists, and they should not be read as one. The first is what happened to healthy people given VIP in a research session. The first list comes from a 2010 study in which all participants received intradermal injections of 200 pmol PACAP38, 200 pmol VIP and placebo into the volar forearm. Intradermal means into the skin itself, and the volar forearm is the soft inner side of the arm. The amount was tiny and chosen to make a local reaction rather than reach the whole body. Even so, VIP induced a considerably larger increase in skin blood flow, flare and wheal than PACAP38 did, in the same healthy volunteers. A flare is the red flush around a jab, and a wheal is the raised bump in the middle. The second list is what its known effects on the body suggest a bigger dose could do, covering blood pressure, heart rate, headache and the airways, and it is taken apart further down. The third list comes from the aviptadil trials in hospital patients, counted in the next section.

Question 2

What did the aviptadil trials record about harm?

Accepted Answer

The largest count comes from TESICO, a placebo-controlled trial at 28 US sites in adults with COVID-19 respiratory failure, where 431 (94%) of 461 participants were in an intensive care unit at baseline. Its main safety measure bundled death, serious adverse events, organ failure, serious infection and grade 3 or 4 adverse events over the first five days. That bundle occurred in 146 of 231 patients given aviptadil and in 129 of 230 given placebo, an odds ratio of 1·40 with a 95% confidence interval from 0·94 to 2·08. The difference leaned against aviptadil without reaching statistical significance. An earlier 196-patient infusion trial reported, in its authors' words, the absence of drug-related serious adverse events. The smaller studies were quieter. In an 80-patient inhaled trial there was no drop-out due to side effects, and in six patients with severe viral lung failure no adverse effects were noted. Small studies can miss uncommon harms, so a quiet small study is not the same as a clean record.

Question 3

Is VIP peptide legal to use?

Accepted Answer

The sources record regulatory actions rather than law, and those actions concern one combined injection. A 2001 review traces the history of the erectile dysfunction product that paired VIP with phentolamine. All clinical trials were placed on hold in August 1999 after the FDA advised the MCA of safety concerns regarding a competitor's phentolamine mesylate product, the MCA being the British regulator of that time. The worry came from rodents: the FDA recommended a two-year rodent study of aviptadil as a result of previously reported brown adipose tissue proliferations observed in the course of a competitor's rodent study in which phentolamine mesylate was administered daily. Brown adipose tissue is a heat-producing kind of fat. In August 2000, the MCA lifted the hold on trials stating the findings do not represent a significant carcinogenic risk in man, and UK approval followed that October. None of that touches VIP sold on its own, and whether a person may buy or hold such a vial depends on where they live, which none of these sources covers.

Question 4

Does VIP lower blood pressure?

Accepted Answer

Yes, by design of the molecule, and this is the effect most likely to matter outside a skin test. A 2001 review of its effects on the heart and vessels reports that VIP lowers mean arterial pressure by 10-15%, while also strengthening the heart's contraction. Mean arterial pressure is the average pressure in the arteries across one heartbeat. The same review puts its strength in context: on a molar basis, VIP is 50-100 times more potent than acetylcholine as a vasodilator. A vasodilator widens blood vessels, and wider vessels mean lower pressure. That is exactly why VIP sits on development lists for high blood pressure. The same property is the obvious risk for somebody whose pressure is normal or low, or who takes a medicine that lowers it. The review's figure is drawn from animal and clinical procedure work rather than from a person injecting VIP at home. One human measurement points the other way for the inhaled form: in 20 patients with high lung pressure, a breathed-in dose reduced the strain on the right side of the heart without affecting systemic blood pressure. Inhaled and injected VIP are different exposures, so neither result answers for the other.

Question 5

What does VIP do to heart rate and the heartbeat?

Accepted Answer

It speeds the heart and makes it beat harder, both strongly. The 2001 review states that endogenously released or exogenous VIP can significantly increase the heart rate and has a more potent effect on heart rate than does norepinephrine. Endogenous means made by the body, and exogenous means given from outside. Norepinephrine is the body's own fight-or-flight signal, so being stronger than it on heart rate is a large effect. In heart muscle studied in the lab, VIP augments developed isometric force and increases atrial and ventricular contractility at concentrations of 10(-8)-10(-5) mol. Contractility is how forcefully the heart squeezes. A faster, harder heartbeat with lower pressure is a pattern a healthy heart may cope with and a diseased one may not, and the lab figures leave open where that line falls. Strength in a dish is not the same as harm in a person. None of the human studies covered here was set up to watch the heart over time, so whether these effects cause trouble in a person with a heart condition has not been studied.

Question 6

Can VIP trigger a headache or migraine?

Accepted Answer

It can cause a mild headache, and in the one published trial in migraine patients it did not set off a migraine. In 2008, twelve patients with migraine without aura received an infusion of VIP and, on another day, placebo, with neither they nor the staff told which was which. VIP induced a mild immediate headache (maximum 2 on VRS) compared with placebo, VRS being a verbal rating scale on which higher numbers mean worse pain. Three patients reported delayed headache (3-11 h after infusion) after VIP and two after placebo, which is no real difference. None of the subjects reported a migraine attack after VIP infusion, even though the temple artery widened by nearly half. Two registered trials built to induce headache in healthy volunteers are listed as completed, with no result in the sources cited on this page. A clinical guide to the migraine drug zolmitriptan still traces migraine to widened blood vessels in the head together with a release of nerve peptides, VIP among them. Twelve patients in one trial narrow the question rather than close it.

Question 7

Could VIP make asthma or allergies worse?

Accepted Answer

This cuts both ways, and the two findings come from very different setups. On one side, a 1984 study found that VIP relaxes isolated strips of human bronchus in the lab, the tubes that carry air into the lungs. Relaxing those tubes opens the airway, which is what an asthma reliever does. On the other side, a 2015 mouse study found that VIP then stimulates CD4(+) and resident innate lymphoid type 2 cells, creating an inflammatory signaling loop that promotes allergic inflammation. Those are immune cells that drive allergic reactions. In that work, VIP released from the animals' own nerves fed the allergy rather than calming it. Silencing the nerves that release it substantially reduced ovalbumin- or house-dust-mite-induced airway inflammation in those mice. A relaxed strip of airway in a dish and an inflamed airway in a living mouse are different questions. Neither was tested in a person with asthma among the research behind this page.

Question 8

What does VIP interact with?

Accepted Answer

Three interactions are on record, and none of them comes from a person taking VIP alongside a medicine. In the 1984 lung strip work, soaking the tissue first in indomethacin made the relaxing effect of VIP markedly stronger. Indomethacin is a common anti-inflammatory painkiller, so that is a laboratory hint that a familiar medicine can change how hard VIP acts. In dialysis patients given cinacalcet, a 2008 study found their VIP levels had dropped four hours later. Cinacalcet is a medicine for overactive parathyroid glands. That finding concerns the body's own VIP rather than an injected dose. A clinical guide to zolmitriptan, a migraine drug, says it stops nerve endings in the head from releasing inflammatory peptides, the group VIP belongs to. Add the blood-pressure effect above, and anything else that lowers pressure is an untested pairing rather than a known one.

Question 9

Is there a link between VIP and mental health?

Accepted Answer

There is a gene finding, and it is easy to over-read. A 2011 study found duplications near the VIP receptor gene in 29 of 8,290 (0.35%) patients versus 2 of 7,431 (0.03%) controls in the combined sample. The patients had schizophrenia, and the duplications were in the gene for VPAC2, one of the receptors VIP acts on. In cells from those patients, VIPR2 transcription and cyclic-AMP signalling were significantly increased in cultured lymphocytes, meaning the receptor's signal was turned up. Lymphocytes are white blood cells, used here because they are easy to sample. So in a rare genetic group, more VIP-receptor signalling went with a serious psychiatric illness. That is a reason the question is worth asking. It is not evidence that injecting VIP affects the mind, which is a different experiment and has not been done in these sources.

Question 10

Does a VIP scan carry its own risk?

Accepted Answer

Yes, but the risk belongs to the radioactive label rather than the peptide. In 1995, VIP tagged with radioactive iodine was given to 18 patients with bowel or hormone-producing tumours so the tumours would show up on a scan. The study calculated the highest radiation absorbed doses for the lungs, urinary bladder and thyroid gland, with the thyroid highest at 104 muGy/MBq. The thyroid takes up iodine, which is why it gets the most radiation from an iodine label. The body cleared it quickly, as radioactivity was excreted into the urine and amounted to 93% of the injected dose within 24 hours. The authors called the dose figures favourable for a scanning agent. That judgement is about radiation in a one-off scan, and it says nothing about the peptide given repeatedly without a label.

Question 11

Is VIP hard on the liver or kidneys?

Accepted Answer

Nothing among the research behind this page measured liver or kidney damage in a person given VIP. What exists is two indirect facts. The kidneys clear it, as the tracer study showed, with most of an injection passing into the urine within a day. Being cleared by an organ is not the same as harming it. On the liver side, a 2018 review notes that the vagus nerve releases other neurotransmitters such as vasoactive intestinal peptide (VIP), which also modulates liver injury responses and hemodynamics. Hemodynamics means blood flow. That sentence is about the body's own VIP, released by a nerve inside the liver, and the review does not say in which direction it moves injury. The same review stresses how limited this understanding is, saying knowledge of the post-neuronal modulation of liver injury in models utilizing vagus nerve activity remains limited. So the organ question is open in both directions rather than answered.

Question 12

How long does the human safety record for VIP run?

Accepted Answer

Longer than it once did, though still short for anything a person might use for months. The research injections were watched over minutes, and the tracer study followed its radioactive label for a day, with peak lung activity of 40% of the injected dose at 0.7 hr falling to 8% at 22 hours. The aviptadil trials stretched that. TESICO gave its infusion over 12 hours a day for three days and followed patients to day 90, by which point 38% of the aviptadil group and 36% of the placebo group had died. A planned European study set inhaled doses three times a day for 10 days, and no result from it appears among the sources cited on this page. The longest human record is for the erectile dysfunction injection, where a retrospective series followed 308 men with a mean follow-up period of 13.3 months. That series reports how many men found it effective, and its abstract gives no adverse-event rate, so the longest exposure is also the one with the thinnest harm count.

Question 13

What harms come with the erectile dysfunction injection?

Accepted Answer

The sources describe the class of penile injections better than this one combination. A 2019 systematic review of injections into the penis found adverse events in ≤ 26% of patients across the agents it covered, with early discontinuation rates of ≤ 38%, often within the first months. A 2024 history of the field names priapism, an erection that will not go down, as the most common side effect, with the greatest risk of this from papaverine, which is a different agent. The reason the VIP combination was used at all is a harm elsewhere. A 2025 report notes that the standard injection, alprostadil, can cause pain (12%) and priapism (1%), and men in its 308-patient series were referred after intolerable pain or failure on it. That report measures how often the VIP and phentolamine injection worked, and its abstract gives no rate of pain or priapism on it. So the class figures are the nearest measure, and they belong to the class rather than to this combination.

Question 14

Who was kept out of the aviptadil trials?

Accepted Answer

Trial exclusions are the nearest thing these sources offer to a list of people at higher risk, and the two are not the same. The European inhaled study gave its key exclusion criteria as mechanical ventilation at baseline, need for intensive care at baseline, and severe hemodynamic instability, which means a dangerously unstable circulation. TESICO kept a separate group for patients eligible for randomisation to remdesivir only because aviptadil was contraindicated, and the trial report among these sources does not list those reasons. Pregnancy sat outside the main trials. A 2022 report describes a woman at 27 weeks of pregnancy who was ineligible for phase 3 trials of Aviptadil and was treated under an expanded access protocol, a route for giving an unapproved agent outside a trial. Her authors read her recovery as support for using it in pregnancy, but one patient is a case, and a case cannot settle a question like that. The erectile dysfunction series took only men whose earlier injections had failed or hurt, so its findings describe that group.

VIP side effects and safety data